{"id":"W4281986919","doi":"10.1200/jco.2022.40.16_suppl.7549","title":"Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Progressive disease; Progression-free survival; Bruton's tyrosine kinase; Phases of clinical research; Tolerability; Nausea; Ibrutinib; Oncology; Clinical trial; Surgery; Adverse effect; Chronic lymphocytic leukemia; Chemotherapy; Leukemia; Tyrosine kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001651948,0.0007057912,0.000965686,0.0003128907,0.000221887,0.0006002742,0.0004878927,0.0006093378,0.002274513],"category_scores_gemma":[0.0009073755,0.0002266138,0.0006700717,0.0003346057,0.0004053446,0.0005779047,0.0002234847,0.001204161,0.0005450327],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005445466,"about_ca_system_score_gemma":0.000653132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007205695,"about_ca_topic_score_gemma":0.00209966,"domain_scores_codex":[0.9996467,0.0001959398,0.00002286214,0.00004943816,0.00003310554,0.00005196137],"domain_scores_gemma":[0.99946,0.0001181557,0.0001308791,0.00003105628,0.00003588094,0.0002240949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6822274,0.0292927,0.03044818,0.001532219,0.002889441,0.0005157912,0.0004412129,0.001797754,0.03650305,0.0002674487,0.008240394,0.2058445],"study_design_scores_gemma":[0.657231,0.2728822,0.05804584,0.00008789657,0.001286486,0.0007123123,0.000117311,0.001715013,0.00214364,0.0002413071,0.005505851,0.00003120408],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905136,0.005474954,0.0002732794,0.0003420426,0.00005161505,0.000925061,0.0009999677,0.00006049034,0.001359028],"genre_scores_gemma":[0.9917943,0.002477749,0.0009341894,0.0007514455,0.0001796798,0.0008280114,0.002182174,0.00001581424,0.0008366588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002274513,"threshold_uncertainty_score":0.008736432,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1423006420353606,"score_gpt":0.4852941723705371,"score_spread":0.3429935303351764,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}